PA
TVRD

Profund Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Profund Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-336
Closed -$59.3K – 1151
2023
Q1 		$59.3K Buy
+336
New +$113K ﹤0.01% 1076

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Profund Advisors's TVRD Position: Q2 2023 in Review

Profund Advisors sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 336 shares — an estimated $59.3K sold.

Profund Advisors first reported a position in TVRD in Q1 2023 and held it in 1 quarter. The position peaked at $59.3K in Q1 2023. 136 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

  • Profund Advisors reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Profund Advisors sold 336 Tvardi Therapeutics shares in Q2 2023, an estimated $59.3K.
  • Profund Advisors first reported a position in Tvardi Therapeutics in Q1 2023 and held it in 1 quarter.
  • Profund Advisors's Tvardi Therapeutics position peaked at $59.3K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on Profund Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.